| 0.241 -0.002 (-0.82%) | 06-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Based in Salt Lake City, Utah, PolarityTE, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of regenerative tissue products and biomaterials. Its offerings serve the medical, biomedical engineering, and material sciences sectors across the United States. The company operates through two primary divisions: Regenerative Medicine Products and Contract Services. PolarityTE's key product is SkinTE, a specialized tissue solution employed for the repair, reconstruction, replacement, or augmentation of skin in patients. Its applications encompass treating acute or chronic wounds, burns, surgical reconstruction, scar revision, and the removal of dysfunctional skin grafts. In addition to its product line, the firm also provides contract research services. The company's pipeline includes SkinTE Cryo, which facilitates multiple deployments from a single harvest through a cryopreservation process, and a SkinTE point-of-care device designed for immediate processing and application of SkinTE directly after initial harvest. PolarityTE is also advancing PTE 11000, an allogenic, biologically active dressing engineered to accelerate healing in both wound care and aesthetic contexts, alongside other promising tissue regeneration products.
Fri, 18 Aug 2023
PolarityTE, Inc. has Changed its Name to RegenETP, Inc - marketscreener.com
Tue, 27 Dec 2022
PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company - PR Newswire
Tue, 18 Feb 2020
The Bear Cave (Issue #1🎉🎉) - The Bear Cave | Edwin Dorsey
Thu, 18 Oct 2018
PolarityTE Issues Statement on Misleading Internet Post - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|